France is the 2nd European market for medicines and medical devices
The sector has 3000 companies and a turnover of 90 billion € in 2019
Investment funds have allocated 340 million euros to bio-tech startups
The goal of the transformation of the health system is to be more patient-oriented and improve the quality of life of French people.
Innovation in health concerns:
- The quality, relevance and modes of financing of care
- Investments for research (advanced technology, AI, medtechs, biotechs, e-health, etc.)
- The digitalization of the customer journey through remote medical consultation platforms, shared medical records, etc.
- Territorial organization for better coordination of public and private actors
In addition, following the health crisis, numerous investments in R&D will be made to relocate the production activities of pharmaceutical laboratories in France.